CLDN18 and gastric cancer: After identifying the increased occurrence of the CLDN18-ARHGAP fusion gene among GC patients, we next aimed to investigate whether neoantigens derived from CLDN18-ARHGAP fusions could elicit immunostimulatory T-cell responses.